Clinical trial · Interventional
ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation
Prospective, Multi-Center Study of the ClariCore Optical Biopsy System in Patients Undergoing Transrectal Ultrasound (TRUS)-Guided Prostate Biopsy for Real-Time Tissue Evaluation
NCT03504761CI-TRIAL-00037069SCOREunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to demonstrate the effectiveness and safety of the ClariCore System in obtaining prostate biopsies with device feedback that provides real-time tissue classification.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cellular Diagnosis, Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ClariCore Optical Biopsy System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ClariCore System
- description
- ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
- interventionNames
- Device: ClariCore Optical Biopsy System
Primary outcomes (1)
- measure
- Validation of the tissue classification algorithm
- timeFrame
- At time of procedure
- description
- Correlate histopathology of tissue biopsy core samples with the tissue classification algorithm results obtained at the time of the procedure to validate the tissue classification algorithm.
Secondary outcomes (2)
- measure
- Sensitivity and Specificity
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 22 Years
Show eligibility criteria text
Inclusion Criteria: * Males \> 22 years old * Patient scheduled for TRUS-guided prostate biopsy based on standard of care urologic requirements to assess for tissue malignancy (abnormal Digital Rectum Examination, Prostate Specific Antigen kinetics, age, ethnicity, family history, etc.) * Enrolling physician must have expectation that prostate dimensions will meet minimum prostate volume and height requirements that will be evaluated at start of biopsy procedure (i.e., Prostate volume \> 20cc and height at least 22mm) * Patient signs an Institutional Review Board approved, Informed Consent form to participate in the study prior to any study mandated determinations or procedure Exclusion Criteria: * Any anatomical or co-morbidity contraindications to TRUS prostate biopsy * Acute painful perianal disorder (i.e. rectal abscess) * Symptomatic, acute prostatitis * Surgical absence of a rectum or the presence of a rectal fistula * Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection * Previous prostate intervention \[Transurethral Prostatectomy (TURP) (bipolar, monopolar, laser)\], Transurethral Microwave Thermotherapy (TUMT), High-Intensity Focused Ultrasound (HIFU), Cryo, Rezum, Urolift\], not including previous prostate biopsy * Current use of blood thinning agents for medical comorbidity which prohibits the cessation of use as typically required per standard of care (SOC) or history of a bleeding disorder (e.g. coagulopathy) * Prior pelvic irradiation * Actively receiving therapy for the treatment of cancer (except for patients on 5-alpha reductase inhibitors, or non-melanoma skin cancers that are managed nonsystemically) * Actively receiving intravesical therapy or within 6 months of treatment for bladder cancer * Patient has compromised immune system * Active inflammatory bowel disease within the last 6 months * Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies) * Patient is not likely to comply with the protocol or follow up evaluation * Patient is participating in a clinical trial of another investigational drug or device that may impact participation in this clinical study * Patient is unable to provide legal Informed Consent
References
Publications (0)
Data not yet available
No reference posted for this study.